Disc Medicine Analyst Remains Confident In Rare Disease Drug Despite FDA Action

The U.S. Food and Drug Administration (FDA) reviewers on Thursday postponed their decision on an experimental treatment from Disc Medicine Inc. (NASDAQ:IRON) by about two weeks to Feb.10. • Disc Medicine stock is gaining positive traction. What’s pushing IRON stock higher?The drug, bitopertin, is being developed for erythropoietic protoporphyria, a rare blood disorder that causes extreme sensitivity to sunlight.Regulators questioned whether "pain-free time in the sun," a secondary endpoint in trials, was a ...